Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.
Also called NCT06643819
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 324 participants
- Registry
-
NCT06643819
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06643819. Randomized; double masking; primary purpose treatment. Start 2024-10-14 (actual); primary completion 2026-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- Condition
- Essential Hypertension
- Intervention (Drug)
- Sacubitril∙Valsartan(dose maintenance)
- Intervention (Drug)
- Sacubitril∙Valsartan(dose increasing)
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct06643819- Content hash
f94d59fba9602821e51d327198cf99a1211bfd960fdc915df2d33d7abef636ad